{"id":"conventional-dose-ticagrelor","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Bleeding"},{"rate":"10-20%","effect":"Dyspnea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This action prevents platelets from aggregating and forming blood clots, which can cause heart attacks and strokes. Ticagrelor is a reversible antagonist of the P2Y12 receptor, which is a key player in platelet activation and aggregation.","oneSentence":"Ticagrelor is a platelet aggregation inhibitor that works by blocking the P2Y12 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:38.111Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT05785897","phase":"NA","title":"STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT","status":"RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2025-11-01","conditions":"ST Elevation Myocardial Infarction","enrollment":350},{"nctId":"NCT03465644","phase":"PHASE4","title":"TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI","status":"COMPLETED","sponsor":"Duk-Woo Park, MD","startDate":"2019-02-12","conditions":"Coronary Stenoses","enrollment":2018},{"nctId":"NCT05418556","phase":"PHASE4","title":"Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-10-21","conditions":"Coronary Artery Disease","enrollment":3944},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06013020","phase":"PHASE4","title":"Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus","status":"RECRUITING","sponsor":"Zunyi Medical College","startDate":"2024-04-01","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":374},{"nctId":"NCT04944615","phase":"NA","title":"To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease.","status":"RECRUITING","sponsor":"CCRF Inc., Beijing, China","startDate":"2022-10-21","conditions":"Chronic Total Occlusion of Coronary Artery","enrollment":1448},{"nctId":"NCT05045274","phase":"NA","title":"The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-12","conditions":"STEMI - ST Elevation Myocardial Infarction, Left Ventricular Systolic Dysfunction","enrollment":300},{"nctId":"NCT03533153","phase":"PHASE1, PHASE2","title":"Intravenous MSC Therapy on Ischemia-Reperfusion Injury in Patients With Myocardial Infarction","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2021-03-01","conditions":"Myocardial Infarction","enrollment":90},{"nctId":"NCT03989557","phase":"PHASE4","title":"Application of Platelet Function Test in Prevention of Ischemic Events After Stent Placement in Intracranial Aneurysms","status":"COMPLETED","sponsor":"Beijing Neurosurgical Institute","startDate":"2019-07-01","conditions":"Unruptured Intracranial Aneurysm, Stents, Antiplatelet Drugs","enrollment":314},{"nctId":"NCT02944123","phase":"PHASE3","title":"Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)","status":"COMPLETED","sponsor":"Dong-A University","startDate":"2016-09","conditions":"Acute Coronary Syndrome","enrollment":120},{"nctId":"NCT01962428","phase":"PHASE4","title":"Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI","status":"COMPLETED","sponsor":"General Hospital of Chinese Armed Police Forces","startDate":"2014-06","conditions":"Non ST Segment Elevation Acute Coronary Syndrome","enrollment":250},{"nctId":"NCT01994941","phase":"PHASE4","title":"Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2013-08","conditions":"Acute Coronary Syndrome","enrollment":133},{"nctId":"NCT02514642","phase":"PHASE4","title":"Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2015-07","conditions":"Coronary Artery Disease","enrollment":30},{"nctId":"NCT02415803","phase":"PHASE3","title":"Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2014-12","conditions":"Non ST Segment Elevation Acute Coronary Syndrome","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"conventional-dose ticagrelor","genericName":"conventional-dose ticagrelor","companyName":"First Affiliated Hospital of Harbin Medical University","companyId":"first-affiliated-hospital-of-harbin-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ticagrelor is a platelet aggregation inhibitor that works by blocking the P2Y12 receptor. Used for Atrial fibrillation for stroke prevention, Acute coronary syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}